D.E. Shaw & Co
IMMX icon

D.E. Shaw & Co’s Immix Biopharma IMMX Stock Holding History

D.E. Shaw & Co’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$960K Buy
+93,106
New +$864K ﹤0.01% 3775

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

D.E. Shaw & Co's IMMX Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Immix Biopharma (IMMX) in Q2 2026: 93,106 shares worth $960K. The stake represents ﹤0.01% of the portfolio and ranks #3775 among its holdings.

109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • D.E. Shaw & Co held 93,106 shares of Immix Biopharma worth $960K as of Q2 2026.
  • Immix Biopharma was a new D.E. Shaw & Co position in Q2 2026.
  • Immix Biopharma made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3775 holding.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.